Literature DB >> 25630467

Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery.

Cassandra Koole1, Denise Wootten1, John Simms1, Laurence J Miller1, Arthur Christopoulos1, Patrick M Sexton2.   

Abstract

The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor that has a critical role in the regulation of glucose homeostasis, principally through the regulation of insulin secretion. The receptor system is highly complex, able to be activated by both endogenous [GLP-1(1-36)NH2, GLP-1(1-37), GLP-1(7-36)NH2, GLP-1(7-37), oxyntomodulin], and exogenous (exendin-4) peptides in addition to small-molecule allosteric agonists (compound 2 [6,7-dichloro-2-methylsulfonyl-3-tert-butylaminoquinoxaline], BETP [4-(3-benzyloxy)phenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine]). Furthermore, the GLP-1R is subject to single-nucleotide polymorphic variance, resulting in amino acid changes in the receptor protein. In this study, we investigated two polymorphic variants previously reported to impact peptide-mediated receptor activity (M149) and small-molecule allostery (C333). These residues were mutated to a series of alternate amino acids, and their functionality was monitored across physiologically significant signaling pathways, including cAMP, extracellular signal-regulated kinase 1 and 2 phosphorylation, and intracellular Ca(2+) mobilization, in addition to peptide binding and cell-surface expression. We observed that residue 149 is highly sensitive to mutation, with almost all peptide responses significantly attenuated at mutated receptors. However, most reductions in activity were able to be restored by the small-molecule allosteric agonist compound 2. Conversely, mutation of residue 333 had little impact on peptide-mediated receptor activation, but this activity could not be modulated by compound 2 to the same extent as that observed at the wild-type receptor. These results provide insight into the importance of residues 149 and 333 in peptide function and highlight the complexities of allosteric modulation within this receptor system.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25630467     DOI: 10.1124/jpet.114.220913

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  GLP-1 and IGF-I levels are elevated in late infancy in low birth weight infants, independently of GLP-1 receptor polymorphisms and neonatal nutrition.

Authors:  M Díaz; C García-Beltran; A López-Bermejo; F de Zegher; L Ibáñez
Journal:  Int J Obes (Lond)       Date:  2017-11-01       Impact factor: 5.095

Review 2.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

3.  Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism.

Authors:  Saifei Lei; Lachlan Clydesdale; Antao Dai; Xiaoqing Cai; Yang Feng; Dehua Yang; Yi-Lynn Liang; Cassandra Koole; Peishen Zhao; Thomas Coudrat; Arthur Christopoulos; Ming-Wei Wang; Denise Wootten; Patrick M Sexton
Journal:  J Biol Chem       Date:  2018-05-01       Impact factor: 5.157

Review 4.  Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.

Authors:  Gaia Chiara Mannino; Francesco Andreozzi; Giorgio Sesti
Journal:  Diabetes Metab Res Rev       Date:  2019-01-07       Impact factor: 4.876

5.  Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists.

Authors:  Maria Lucey; Philip Pickford; Stavroula Bitsi; James Minnion; Jan Ungewiss; Katja Schoeneberg; Guy A Rutter; Stephen R Bloom; Alejandra Tomas; Ben Jones
Journal:  Mol Metab       Date:  2020-04-08       Impact factor: 7.422

6.  Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells.

Authors:  Zijian Fang; Shiqian Chen; Yusman Manchanda; Stavroula Bitsi; Philip Pickford; Alessia David; Maria M Shchepinova; Ivan R Corrêa; David J Hodson; Johannes Broichhagen; Edward W Tate; Frank Reimann; Victoria Salem; Guy A Rutter; Tricia Tan; Stephen R Bloom; Alejandra Tomas; Ben Jones
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

Review 7.  Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors.

Authors:  Jasna Klen; Vita Dolžan
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

8.  Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor.

Authors:  Zhaotong Cong; Li-Nan Chen; Honglei Ma; Qingtong Zhou; Xinyu Zou; Chenyu Ye; Antao Dai; Qing Liu; Wei Huang; Xianqiang Sun; Xi Wang; Peiyu Xu; Lihua Zhao; Tian Xia; Wenge Zhong; Dehua Yang; H Eric Xu; Yan Zhang; Ming-Wei Wang
Journal:  Nat Commun       Date:  2021-06-18       Impact factor: 14.919

9.  The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling.

Authors:  Rachel L Dods; Dan Donnelly
Journal:  Biosci Rep       Date:  2015-11-23       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.